To further evaluate the long-term effects of the two antiplatelet strategies on saphenous vein graft patency, long-term adverse cardiovascular events, and bleeding events after coronary artery bypass grafting (CABG), we plan to conduct an extended follow-up study based on the previously completed TOP-CABG trial. This extended follow-up aims to provide high-quality evidence to inform more optimized and individualized long-term antiplatelet management strategies for patients after CABG.
Patients 18-80 of age.
Patients undergo planned CABG for the first time with ≥1 SVGs
Patients with written informed consent.
Concomitant valve (excluding aortic bioprosthesis), aorta, or rhythm surgery during the same session.
Patients undergo emergency CABG.
Patients with single coronary artery disease.
Patients with cardiogenic shock and hemodynamic instability.
The study population consists of participants previously enrolled in the TOP-CABG trial who underwent coronary artery bypass grafting (CABG) with at least one saphenous vein graft and were randomized to either 3-month dual antiplatelet therapy or 12-month dual antiplatelet therapy. Participants who completed the original trial and are eligible for extended follow-up will be included to assess long-term graft-related outcomes, cardiovascular events, bleeding events, quality of life, and other patient-reported outcomes.
Cohort
Prospective
Not listed
Four-point major adverse cardiovascular and cerebrovascular events (4P-MACCE)
The composite of all-cause death, myocardial infarction, stroke, and coronary revascularization.
Five-point major adverse cardiovascular and cerebrovascular events (5P-MACCE)
The composite of all-cause death, myocardial infarction, stroke, coronary revascularization, and hospitalization for unstable angina
Three-point major adverse cardiovascular events (3P-MACE)
The composite of cardiovascular death, myocardial infarction, and stroke
Time to first occurrence of all-cause death
Time to first occurrence of cardiovascular death
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
